[go: up one dir, main page]

EP1107738A4 - Novel pharmaceutical salt form - Google Patents

Novel pharmaceutical salt form

Info

Publication number
EP1107738A4
EP1107738A4 EP99968215A EP99968215A EP1107738A4 EP 1107738 A4 EP1107738 A4 EP 1107738A4 EP 99968215 A EP99968215 A EP 99968215A EP 99968215 A EP99968215 A EP 99968215A EP 1107738 A4 EP1107738 A4 EP 1107738A4
Authority
EP
European Patent Office
Prior art keywords
salt
agent
base
useful
saccharinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99968215A
Other languages
German (de)
French (fr)
Other versions
EP1107738A1 (en
Inventor
James W Rayburn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP1107738A1 publication Critical patent/EP1107738A1/en
Publication of EP1107738A4 publication Critical patent/EP1107738A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a novel salt form of certain pharmacologically active organic bases and their preparation.
  • the class will be exemplified by the saccharinate salt of buspirone, a useful anti-anxiety agent.
  • solubility of the salt is generally less than for more standard pharmaceutical salts such as halides, sulfates, and the like.
  • the saccharinate salt of certain non-al ⁇ kaloidal organic bases provides novel salt forms demonstrating improved organoleptic properties.
  • the saccharinate salt also provides a means of sustaining drug release by virtue of decreased aqueous solubility of the saccharinate compared to more standard pharmaceutical salts such as halides, sulfates, phosphates, and the like.
  • the saccharinate salts are conveniently synthesized by salt interchange on admixture of solutions of sodium saccharinate and acid addition salts; e.g., the hydrochloride salt, of medicinal organic bases.
  • Other salt-forming reactions well-known to one skilled in the pharmaceutical sciences, may also be employed.
  • antiinfectives such as erythromycin
  • analgesics such as codeine, meperidine, pentazocine, butorphanol, buprenorphine;
  • anxiolytics e.g., benzodiazepines such as alprazolam, azapirones such as buspirone;
  • antipsychotics e.g., phenothiazines such as chlorpramazine and thioridazine, piperazines such as fluphenazine, thioxanthenes such as thiothixene, butyrophenones such as haloperidol, dibenzoxapines such as loxapine, dihydroindolones such as molindone; and
  • affective disorder agents such as imipramine, trazodone, nefazodone, fluoxetine, sertraline, and the like, dextroamphetamine and methylphenidate.
  • Neurologies can be represented by procyclidine, biperiden, amantadine and selegiline; ergotamines and methylsergide; scopoiamine, cyclizine, hydroxyzine and the like.
  • Anesthetics are represented by benzocaine, dibucaine, lidocaine, procaine and the like.
  • Respiratory agents are represented by epinephrine, phenylephrine, phenylpropanolamine and pseudoephedrine; isoproterenol and terbutaline.
  • Cardiovasculars can be subclassed as:
  • inotropics such as dobutamine
  • antiarrhythmics such as acecainide, disopipramide;
  • ⁇ -blockers such as propranolol, atenolol, nadolol;
  • calcium blockers such as diltiazem, nifedipine and nimodipine;
  • vasodilators such as papaverine and isoxsuprine
  • antihypertensives such as hydralazine
  • diuretics such as triamterene and amiloride.
  • Endocrine agents such as bromocryptine and clomiphene; and metabolic agents such as phenformin.
  • Gastrointestinal agents such as metaclopramide or cimetidine.
  • the present invention involves stable crystalline saccharinate salts of orally administrable medicinal bases.
  • Saccharin chemically 1 ,2- benzisothiazol-3(2H)-one 1 ,1 , dioxide, is used as a sweetener, most commonly in the form of its sodium salt dihydrate. While it is used as a sweetener in pharmaceutical applications, its use is as a component of a mixture of ingredients.
  • saccharine provides a sweet taste in dilute aqueous solutions where it is about 500 times sweeter than sugar with the sweet taste still detectable in 1 :100,000 dilution; nonetheless saccharin has a bitter, metallic aftertaste. Because saccharin's taste is most pleasant in dilute solution, care must be exercised in formulating saccharin in its solid state because of a very objectionable taste.
  • the current invention relates to actual salt forms, as opposed to mixtures, comprising the organic base cation and the saccharinate anion.
  • the medicinal has pleasant organoleptic properties even in its solid form.
  • the saccharinate salts offer the potential for pharmaceutical formulations without requiring large amounts of other organoleptic enhancers such as sweeteners, flavors, and the like which are usually required to render medicinal bases palatable.
  • organoleptic enhancers such as sweeteners, flavors, and the like which are usually required to render medicinal bases palatable.
  • the advantages of saccharinate salts would especially be evident in formulating oral suspensions, chewable tablets, lozenges, and quick-melt dosage forms.
  • Another aspect of the present invention relates to the general reduction in solubility of the saccharinate salts of the non-alkaloidal medicinal bases compared to more common acid addition salts of the medicinal bases such as hydrohalide, sulfate, phosphate salts and the like.
  • the saccharinate salts offer a method for providing extended release dosing for certain medicinals.
  • Buspirone hydrochloride (8-4[4-(2-pyrimidinyl)-1 -piperazinyl])butyl]-8- azaspiro[4.5]decane-7,9-dione hydrochloride 4.22 g, 10 mmole) dissolved in a minimal amount of water was added to a concentrated solution of sodium saccharinate (2.05 g, 10 mmole) with stirring. The mixture was chilled and the supernatant aqueous layer decanted from the heavier oil layer which was dissolved in methylene chloride. The methylene chloride solution was washed with water and then dried (MgSO . The dried solution was filtered and concentrated in vacuo to a clear oil. Trituration in ether provided a pale yellow saccharinate salt, m.p. 142-145 °C.
  • Plate #1 contained buspirone hydrochloride.
  • Plate #2 contained buspirone saccharinate, and Plate #3 contained 1 :1 molar equivalent amounts of buspirone hydrochloride and sodium saccharinate in the form of a physical mixture.
  • Tasting volunteers were asked to taste each of the samples and give their preference. All volunteers selected Plate #2 (buspirone saccharinate) as the best tasting sample. By contrast, both Plates #1 and #3 were labeled as objectionable to highly objectionable in taste by the volunteers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The saccharinate salt of synthetic non-alkaloidal medicinal organic bases provides a novel salt form possessing improved organoleptic properties as well as reduced solubility.

Description

NOVEL PHARMACEUTICAL SALT FORM
Cross Reference to Related Application
This application claims priority from provisional application USSN 60/098, 154 filed August 27, 1998.
Background of the Invention
The present invention relates to a novel salt form of certain pharmacologically active organic bases and their preparation. The class will be exemplified by the saccharinate salt of buspirone, a useful anti-anxiety agent.
It is known that while many organic bases function as useful pharmacologic agents, nonetheless salt forms are often pharmaceutically preferred for reasons of enhanced solubility, ease of compounding, and stability. It is also well accepted that oral dosing of drugs is a preferred route of administration. However, most organic bases possess a very bitter taste which, for acceptable oral administration, requires masking by various methods familiar to pharmaceutical formulation practitioners such as the incorporation of sweeteners, flavorings, organoleptic enhancers, and the like.
The intense bitter taste of most bases can be relieved somewhat by substituting a salt form of the pharmacologically active agent for the base in pharmaceutical formulations; e.g., the hydrochloride salt. Some salt forms of drugs are more effective than others in reducing the objectionable taste of the pharmaceutical formulation. It is known that patient compliance in adhering to a drug regimen is negatively affected by pharmaceutical products that are objectionable in taste, particularly in instances where the patient disorder is accompanied by loss of appetite, nausea, and vomiting.
In U.S. 4,362,730, Rader, et al. disclosed and claimed the saccharinate salt of vincamine, a pharmaceutically active alkaloid. Vincamine saccharinate was described as having improved solubility and taste characteristics. Greater solubility for the saccharinate salt of vincamine differs from the reduced solubility seen for the saccharinates of the present convention. The present invention concerns a novel salt form of non-alkaloidal medicinal organic bases that renders the normally bitter-tasting drug much more palatable, thereby facilitating its pharmaceutical formulation for oral routes of administration where taste comes into play; such as liquid suspensions, lozenges, chewable tablets, chewing gums, and the like.
When applied to synthetic organic base medicinals, as opposed to alkaloids, solubility of the salt is generally less than for more standard pharmaceutical salts such as halides, sulfates, and the like.
Detailed Description of the Invention
The saccharinate salt of certain non-al\kaloidal organic bases provides novel salt forms demonstrating improved organoleptic properties. For certain medicinals the saccharinate salt also provides a means of sustaining drug release by virtue of decreased aqueous solubility of the saccharinate compared to more standard pharmaceutical salts such as halides, sulfates, phosphates, and the like. The saccharinate salts are conveniently synthesized by salt interchange on admixture of solutions of sodium saccharinate and acid addition salts; e.g., the hydrochloride salt, of medicinal organic bases. Other salt-forming reactions, well-known to one skilled in the pharmaceutical sciences, may also be employed.
Various classes of orally-active non-alkaloidal synthetic medicinal organic bases are intended applications of the present invention. Some of these medicinal bases fall into the following medical use categories:
• antiinfectives such as erythromycin;
• oncolytics;
• analgesics such as codeine, meperidine, pentazocine, butorphanol, buprenorphine;
• psychopharmacologics;
• neurologies;
• anesthetics; • respiratory agents;
• cardiovasculars/cardio-renal agents
• endocrine agents;
• metabolic agents;
• gastrointestinal agents;
• antiallergenics; and
• immunologies.
Psychopharmalogics can be subclassed as:
• anxiolytics; e.g., benzodiazepines such as alprazolam, azapirones such as buspirone;
• antipsychotics; e.g., phenothiazines such as chlorpramazine and thioridazine, piperazines such as fluphenazine, thioxanthenes such as thiothixene, butyrophenones such as haloperidol, dibenzoxapines such as loxapine, dihydroindolones such as molindone; and
• affective disorder agents such as imipramine, trazodone, nefazodone, fluoxetine, sertraline, and the like, dextroamphetamine and methylphenidate.
Neurologies can be represented by procyclidine, biperiden, amantadine and selegiline; ergotamines and methylsergide; scopoiamine, cyclizine, hydroxyzine and the like.
Anesthetics are represented by benzocaine, dibucaine, lidocaine, procaine and the like. Respiratory agents are represented by epinephrine, phenylephrine, phenylpropanolamine and pseudoephedrine; isoproterenol and terbutaline.
Cardiovasculars can be subclassed as:
inotropics such as dobutamine;
antiarrhythmics such as acecainide, disopipramide;
β-blockers such as propranolol, atenolol, nadolol;
calcium blockers such as diltiazem, nifedipine and nimodipine;
vasodilators such as papaverine and isoxsuprine;
antihypertensives such as hydralazine; and
• diuretics such as triamterene and amiloride.
Endocrine agents such as bromocryptine and clomiphene; and metabolic agents such as phenformin.
Gastrointestinal agents such as metaclopramide or cimetidine.
The present invention involves stable crystalline saccharinate salts of orally administrable medicinal bases. Saccharin, chemically 1 ,2- benzisothiazol-3(2H)-one 1 ,1 , dioxide, is used as a sweetener, most commonly in the form of its sodium salt dihydrate. While it is used as a sweetener in pharmaceutical applications, its use is as a component of a mixture of ingredients. While saccharine provides a sweet taste in dilute aqueous solutions where it is about 500 times sweeter than sugar with the sweet taste still detectable in 1 :100,000 dilution; nonetheless saccharin has a bitter, metallic aftertaste. Because saccharin's taste is most pleasant in dilute solution, care must be exercised in formulating saccharin in its solid state because of a very objectionable taste.
By contrast the current invention relates to actual salt forms, as opposed to mixtures, comprising the organic base cation and the saccharinate anion. In this form the medicinal has pleasant organoleptic properties even in its solid form. As such, the saccharinate salts offer the potential for pharmaceutical formulations without requiring large amounts of other organoleptic enhancers such as sweeteners, flavors, and the like which are usually required to render medicinal bases palatable. The advantages of saccharinate salts would especially be evident in formulating oral suspensions, chewable tablets, lozenges, and quick-melt dosage forms.
Another aspect of the present invention relates to the general reduction in solubility of the saccharinate salts of the non-alkaloidal medicinal bases compared to more common acid addition salts of the medicinal bases such as hydrohalide, sulfate, phosphate salts and the like. With reduced solubility drug release is slowed and extended release of the drug usually occurs. Therefore, the saccharinate salts offer a method for providing extended release dosing for certain medicinals.
The present invention is illustrated by the following examples but is not limited to them.
Example 1 - Buspirone Saccharinate
Buspirone hydrochloride (8-4[4-(2-pyrimidinyl)-1 -piperazinyl])butyl]-8- azaspiro[4.5]decane-7,9-dione hydrochloride 4.22 g, 10 mmole) dissolved in a minimal amount of water was added to a concentrated solution of sodium saccharinate (2.05 g, 10 mmole) with stirring. The mixture was chilled and the supernatant aqueous layer decanted from the heavier oil layer which was dissolved in methylene chloride. The methylene chloride solution was washed with water and then dried (MgSO . The dried solution was filtered and concentrated in vacuo to a clear oil. Trituration in ether provided a pale yellow saccharinate salt, m.p. 142-145 °C.
Analysis:
Calculated for C21H31N5O2 β 7H5 O3S: C, 59.14; H, 6.38; N, 14.78; S, 5.64.
Found: C, 59.14; H, 6.46; N, 14.89; S, 5.51. Example 2 - Taste Preference Testing
Under single-blind conditions, three small glass plates were set out for taste-testing. Plate #1 contained buspirone hydrochloride. Plate #2 contained buspirone saccharinate, and Plate #3 contained 1 :1 molar equivalent amounts of buspirone hydrochloride and sodium saccharinate in the form of a physical mixture. Tasting volunteers were asked to taste each of the samples and give their preference. All volunteers selected Plate #2 (buspirone saccharinate) as the best tasting sample. By contrast, both Plates #1 and #3 were labeled as objectionable to highly objectionable in taste by the volunteers.

Claims

Claims
1. The saccharinate salt of non-alkaloidal organic medicinal bases capable of acid addition salt formation.
2. The salt of claim 1 wherein the base is a useful non-alkaloidal orally- active drug selected from the group consisting of psychopharmaeologics, analgesics, neurologies, anesthetics, respiratory agents, cardiovascular-renal agents, hematologic agents, endocrine and metabolic agents, gastrointestinal agents, dermatologic agents, antiinflammatories, antiallergics, immunologies, oncolytics, and antiinfectives.
3. The salt of claim 2 wherein the base is a useful orally-active antiinfective agent.
4. The salt of claim 2 wherein the base is a useful orally-active analgesic agent.
5. The salt of claim 2 wherein the base is a useful orally-active cardiovascular-renal agent.
6. The salt of claim 2 wherein the base is a useful orally-active gastrointestinal agent.
7. The salt of claim 2 wherein the base is a useful orally-active neurologic agent.
8. The salt of claim 2 wherein the base is a useful orally-active psychopharmacologic agent.
9. The psychopharmacologic agent of claim 8 that is useful in depression.
10. The psychopharmacologic agent of claim 8 that is useful in anxiety.
11. The psychopharmacologic agent of claim 10 that is an azapirone.
12. The azapirone of claim 11 selected from buspirone and gepirone.
13. The azapirone of claim 11 is buspirone saccharinate.
14. The method of producing a saccharinate salt comprising the mixing of a solution of an acid addition salt of the medicinal base with a solution of sodium saccharinate.
EP99968215A 1998-08-27 1999-08-26 Novel pharmaceutical salt form Withdrawn EP1107738A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9815498P 1998-08-27 1998-08-27
US98154P 1998-08-27
PCT/US1999/019575 WO2000012067A1 (en) 1998-08-27 1999-08-26 Novel pharmaceutical salt form

Publications (2)

Publication Number Publication Date
EP1107738A1 EP1107738A1 (en) 2001-06-20
EP1107738A4 true EP1107738A4 (en) 2003-01-22

Family

ID=22267557

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99968215A Withdrawn EP1107738A4 (en) 1998-08-27 1999-08-26 Novel pharmaceutical salt form

Country Status (6)

Country Link
EP (1) EP1107738A4 (en)
JP (1) JP2003525855A (en)
CN (1) CN1348363A (en)
AU (1) AU6021199A (en)
CA (1) CA2341522A1 (en)
WO (1) WO2000012067A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19940740A1 (en) 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmaceutical salts
DE10013712A1 (en) * 2000-03-20 2001-09-27 Nutrinova Gmbh Nicotine salts with improved taste, process for their preparation and their use
DE10045521A1 (en) 2000-03-31 2001-10-04 Roche Diagnostics Gmbh Determining amplification efficiency of a target nucleic acid comprises measuring real-time amplification of diluted series, setting signal threshold value, and determining cycle number at which threshold is exceeded
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10109763A1 (en) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmaceutical salts
DE10130504B4 (en) 2001-06-25 2005-02-03 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Xanthine and phenazone acesulfame H complexes with improved taste, process for their preparation and their use
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (en) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド GABA receptor-mediated regulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2220098A2 (en) * 2007-12-12 2010-08-25 Ultimorphix Technologies B.v. Solid forms of tenofovir disoproxil
US7935817B2 (en) 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
DE202010001237U1 (en) 2010-01-21 2010-04-01 Grünenthal GmbH Combination of tramadol and acetaminophen as effervescent tablet
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
TW201517906A (en) * 2013-07-25 2015-05-16 Almirall Sa Combinations comprising MABA compounds and corticosteroids
TW201617343A (en) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities
CN107868117B (en) * 2016-09-28 2021-04-23 中国科学院苏州纳米技术与纳米仿生研究所 Stanozolol saccharin salt and its preparation method and application
NL2031332B1 (en) 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of psychoactive compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1656M (en) * 1960-12-19 1963-01-14 Tanabe Seiyaku Co Medicinal product based on addition salts of benzophenone-2-carboxylic acid and 1-methyl-3- (di-2-thienylmethylene) -piperidine.
EP0229000A2 (en) * 1986-01-07 1987-07-15 Warner-Lambert Company Encapsulation composition for use with chewing gum and edible products

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1288002A (en) * 1954-06-14 1962-03-24 Pfizer & Co C Improvements in manufacturing processes for imidazoline compounds
US5837277A (en) * 1992-06-04 1998-11-17 Smithkline Beecham Corporation Palatable pharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1656M (en) * 1960-12-19 1963-01-14 Tanabe Seiyaku Co Medicinal product based on addition salts of benzophenone-2-carboxylic acid and 1-methyl-3- (di-2-thienylmethylene) -piperidine.
EP0229000A2 (en) * 1986-01-07 1987-07-15 Warner-Lambert Company Encapsulation composition for use with chewing gum and edible products

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002221043, Database accession no. 1963:461311 *
See also references of WO0012067A1 *

Also Published As

Publication number Publication date
JP2003525855A (en) 2003-09-02
WO2000012067A1 (en) 2000-03-09
CA2341522A1 (en) 2000-03-09
CN1348363A (en) 2002-05-08
AU6021199A (en) 2000-03-21
EP1107738A1 (en) 2001-06-20

Similar Documents

Publication Publication Date Title
EP1107738A1 (en) Novel pharmaceutical salt form
US5811436A (en) Oral liquid compositions containing paroxetine resinate
US6306904B1 (en) Antihistaminic/antitussive compositions
US20030083354A1 (en) Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US6037358A (en) Decongestant/antihistaminic compositions
EP1082109B1 (en) Oral formulation comprising biguanide and an organic acid
HU204994B (en) Process for producint new ranitidine derivatives and pharmaceutical compositions comprising same
KR850001883B1 (en) Method for preparing crystalline benzothiazine dioxide salts
JP3465820B2 (en) Trobafloxacin oral suspension
US3976787A (en) Pharmaceutical guanidine preparations and methods of using same
US6462094B1 (en) Decongestant/expectorant compositions
EP1778183B1 (en) Liquid paroxetine compositions
EP0194336A2 (en) Oral mobenzoxamine preparation
SK15472001A3 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
EP1452169B1 (en) Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen
MXPA01000867A (en) Novel pharmaceutical salt form
US6586469B2 (en) Antihistaminic/antitussive compositions
WO2003086356A1 (en) Diphenhydramine tannate solid dose compositions and methods of use
US6566396B2 (en) Antitussive/antihistaminic compositions
JPS6350355B2 (en)
US20030044461A1 (en) Antitussive/expectorant compositions
EP0431759A1 (en) Process for the preparation of a ranitidine resin absorbate
CA1117528A (en) Glaucine phosphate salts
JPS62142175A (en) Production of (-)eburunamenine-14(15h)-1 resinate
HK1012288B (en) Oral liquid compositions containing paroxetine resinate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20021211

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030301